Immunosuppressive agents in clinical trials in transplantation

American Journal of the Medical Sciences

Volumn 313, Issue 5, 1997, Pages 283-288

  Halloran, Philip F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cyclosporine; Humanized monoclonal antibodies; Immunosuppression; Mycophenolate mofetil; Sirolimus; Tacrolimus

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; BREQUINAR; CELL ADHESION MOLECULE; CYCLOSPORIN; CYCLOSPORIN G; CYTOKINE; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; LYMPHOCYTE ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MIZORIBINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEPTIDE; POLYCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS;

ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; THROMBOCYTOPENIA;

EID: 0030947210     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199705000-00007     Document Type: Article

References (39)

1. Batiuk TD, Pazderka F, Halloran PF. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine- treated patients. Transplantation. 1995;59:1400-4.
2. Pai SY, Fruman DA, Leong T, Neuberg D, Rosano TG, McGarigle C, et al. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood. 1994;84:3974-9.
3. 50 for in vivo cyclosporine in mouse. Transplantation. 1996; 61:1618-24.
4. Pazderka F, Enns J, Batiuk TD, Halloran PF, The functional consequences of partial calcineurin inhibition in human peripheral blood mononuclear leucocytes. Transpl Immunol. 1996;4:23-31.
5. Batiuk TD, Pazderka F, Enns J, DeCastro L, Halloran PF. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest. 1995; 96:1254-60.
6. Kovarik JM, Mueller EA, Richard F, Niese D, Halloran PE, Jeffery J, et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation. 1996;62:759-63.
7. Neumayer HH, Färber L, Haller P, Kohnen E, Maibücher A, Schuster A, et al. Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts: results after 1 month. Transplant Proc. 1994; 26:2944-8.
8. The Canadian Neoral Renal Transplantation Study Group. A randomized, prospective multicentre pharmacoepidemiologic study of Neoral (cyclosporine emulsion) in stable renal graft recipients. Transplantation. 1996;62:1744-52.
9. Schroeder TJ, Levy R, Pouletty P, First MR. A generic cyclosporine formulation development program (abstract), J Am Soc Nephrol. 1996;7:1923.
10. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: A new immunosuppressive agent. Am J Health-Syst Pharm 1995;52:1521-35.
11. Griffith JP, Kim JL, Kim EE, Sintchak MD, Thomson JA, Fitzgibbon MJ, et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell. 1995;82:507-22.
12. Kissinger CR, Parge HE, Knighton DR, Lewis CT, Pelletier LA, Tempczyk A, et al. Crystal structure of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature. 1995;378:641-4.
13. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol. 1993;17:60-8.
14. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-30.
15. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994; 344:423-8.
16. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation. 1995;60:1384-8.
17. Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. one-year follow-up of an open-label trial of FK506 for primary kidney transplantation: A report of the US Multicenter FK506 Kidney Transplant Group. Transplantation. 1996;61:1576-81.
18. Gruessner RWG, Burke GW, Stratta R, Sollinger H, Benedetti E, Marsh C, et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation. 1996; 61:261-73.
19. Keenan RJ, Konishi H, Kawai A, Paradis IL, Nunley DR, Iacono AT, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorae Surg. 1995;60:580-5.
20. Starzl TE, Donner A, Eliasziw M, Stitt L, Meier P, Fung JJ, et al. Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet. 1995;346:1346 -50.
21. Smith JD, Rose ML, Pomerance A, Burke M, Yacoub MH. Reduction of cellular rejection and increase in longer-term survival after heart transplantation after HLA-DR matching. Lancet 1995;346:1318-22.
22. Morris RE, Brown Jr BW. Commentary regarding tacrolimus for prevention of liver allograft rejection: Clinical trials and tribulations (346:1346, 1995). Lancet. 1995;346:1310-1.
23. Atkison P, Joubert G, Barron A, Grant D, Paradis K, Seidman E, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet. 1995;345:894-6.
24. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annn Rev Immunol. 1996:483-510.
25. Sollinger HW. Mycophenolate mofetil. Kidney Int. 1995; 48:S14-7.
26. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029-37.
27. U.S. Renal Transplant Mycophenolate Mofetil Study Group, Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995;60:225-32.
28. Danovitch GM. Mycophenolate mofetil in renal transplantation: Results from the U.S. randomized trials. Kidney Int 1995;48:S93-6.
29. European Mycophenolate Mofetil Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;345:1321-5.
30. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation. 1996;61:722-9.
31. The International MMF Renal Transplant Study Group. A pooled analysis of three randomized double-blind clinical studies in prevention of rejection with mycophenolate mofetil in renal allograft recipients. Transplantation. 1997. In press.
32. Senda M, DeLustro B, Eugui E, Natsumeda Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation. 1995;60:1143-8.
33. Laurent AF, Dumont S, Poindron P, Muller CD. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol. 1996;24:59-67.
34. Shaw LM, Nowak I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit. 1995; 17:685-9.
35. Watson CA, Petzelbauer P, Zhou J, Pardi R, Bender JR. Contact-dependent endothelial class II HLA gene activation induced by NK cells is mediated by IFN-g-dependent and-independent mechanisms. J Immunol. 1995;154:3222-33.
36. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation, 1996;62:666-72.
37. Larsen CP, Elwood ET, Alexander DZ, SC, Hendrix R, Tucker-Burden C, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381:434-8.
38. Nisco S, Vriens P, Hoyt G, Lyu SC, Farfan F, Pouletty P, et al. Induction of allograft tolerance in rats by an HLA class I-derived peptide and cyclosporine A. J Immunol. 1994;152:3786-92.
39. Sayegh MH, Watschingcr B, Carpenter CB. Mechanisms of T cell recognition of alloantigen. The role of peptides. Transplantation. 1994;57:1295-1302.